Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) shares rose 9.4% during mid-day trading on Friday . The company traded as high as $5.90 and last traded at $6.04. Approximately 5,924,028 shares changed hands during trading, a decline of 65% from the average daily volume of 16,866,434 shares. The stock had previously closed at $5.52.
Analysts Set New Price Targets
Several equities analysts have recently weighed in on RXRX shares. Needham & Company LLC reaffirmed a "buy" rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a report on Tuesday, July 8th. Morgan Stanley initiated coverage on shares of Recursion Pharmaceuticals in a report on Thursday, July 3rd. They issued an "equal weight" rating and a $5.00 price target for the company. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to MarketBeat, Recursion Pharmaceuticals currently has a consensus rating of "Hold" and a consensus price target of $7.00.
View Our Latest Analysis on RXRX
Recursion Pharmaceuticals Price Performance
The firm has a market cap of $2.66 billion, a PE ratio of -3.66 and a beta of 0.91. The stock's fifty day moving average price is $4.92 and its 200-day moving average price is $6.00. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.11 and a quick ratio of 4.11.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 74.70% and a negative net margin of 961.32%. The business had revenue of $14.75 million for the quarter, compared to analysts' expectations of $18.12 million. During the same period in the previous year, the company earned ($0.39) EPS. Recursion Pharmaceuticals's quarterly revenue was up 7.2% compared to the same quarter last year. As a group, equities analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of the stock. Brighton Jones LLC raised its holdings in Recursion Pharmaceuticals by 49.4% in the fourth quarter. Brighton Jones LLC now owns 20,261 shares of the company's stock valued at $137,000 after acquiring an additional 6,699 shares in the last quarter. Victory Capital Management Inc. raised its holdings in Recursion Pharmaceuticals by 45.7% in the fourth quarter. Victory Capital Management Inc. now owns 39,913 shares of the company's stock valued at $270,000 after acquiring an additional 12,519 shares in the last quarter. Proficio Capital Partners LLC acquired a new stake in Recursion Pharmaceuticals in the fourth quarter valued at approximately $163,000. Raymond James Financial Inc. acquired a new stake in Recursion Pharmaceuticals in the fourth quarter valued at approximately $609,000. Finally, PNC Financial Services Group Inc. raised its holdings in Recursion Pharmaceuticals by 220.7% during the fourth quarter. PNC Financial Services Group Inc. now owns 9,820 shares of the company's stock worth $66,000 after purchasing an additional 6,758 shares in the last quarter. Hedge funds and other institutional investors own 89.06% of the company's stock.
Recursion Pharmaceuticals Company Profile
(
Get Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Featured Stories
Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access